Zosuquidar (LY335979) 3HCl: Precise P-gp Inhibition for Multidrug Resistance Reversal

Executive Summary: Zosuquidar (LY335979) 3HCl is a highly selective and potent inhibitor of human P-glycoprotein (P-gp), an ATP-dependent efflux transporter central to multidrug resistance (MDR) in cancer cells (Sun et al., 2025). Zosuquidar restores sensitivity to chemotherapeutics such as vinblastine and doxorubicin in both in vitro and in vivo models (Zosuquidar: P-glycoprotein Modulator). The compound has demonstrated efficacy in murine MDR leukemia, and in clinical phase I/II trials with non-Hodgkin's lymphoma and solid tumors, showing minimal added toxicity (APExBIO). Zosuquidar acts through competitive inhibition at the P-gp substrate binding site, and does not alter the pharmacokinetics of co-administered drugs. Its chemical profile and storage parameters are well-defined, supporting reproducible research workflows.

Biological Rationale

P-glycoprotein (P-gp, ABCB1) is an ATP-binding cassette (ABC) transporter expressed in the plasma membrane of cells in the intestine, liver, brain, kidney, and various tumors. P-gp actively effluxes a broad spectrum of xenobiotics and chemotherapeutic agents, contributing to MDR by lowering intracellular drug concentrations (Sun et al., 2025). Overexpression of P-gp is a clinically validated mechanism of chemotherapy failure, particularly in acute myeloid leukemia (AML), non-Hodgkin's lymphoma, and multiple solid tumors. Pharmacological inhibition of P-gp is a rational strategy to enhance intracellular retention and efficacy of cytotoxic drugs (Zosuquidar: Selective P-gp Inhibitor).

Mechanism of Action of Zosuquidar (LY335979) 3HCl

Zosuquidar (LY335979) 3HCl is a synthetic, trihydrochloride salt of a potent P-gp inhibitor with the chemical name (2R)-1-(4-((1aR,10bS)-1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c][7]annulen-6-yl)piperazin-1-yl)-3-(quinolin-5-yloxy)propan-2-ol (molecular weight: 527.6 Da, CAS: 167354-41-8) (APExBIO). It binds competitively to the drug substrate site of P-gp, blocking ATP hydrolysis-linked efflux of chemotherapeutic agents (e.g., vinblastine, doxorubicin, etoposide, paclitaxel) (Systems Pharmacology of Zosuquidar). Zosuquidar exhibits high selectivity for P-gp over other ABC transporters, including MRP1 and BCRP, at low micromolar concentrations (typically 0.1–1 μM in vitro). This specificity minimizes off-target effects and supports robust MDR reversal in P-gp overexpressing cell lines and animal models.

Evidence & Benchmarks

• Zosuquidar restores vinblastine sensitivity in P-gp overexpressing leukemia cells at 0.1–1 μM, reducing the IC₅₀ by >10-fold (Sun et al., 2025).
• In murine models of MDR leukemia, co-administration of zosuquidar and doxorubicin prolongs survival compared to chemotherapy alone, without altering drug pharmacokinetics (Precision Reversal of MDR).
• Phase I/II studies in non-Hodgkin's lymphoma and advanced solid tumors (e.g., with CHOP or vinorelbine) demonstrate effective P-gp inhibition and minimal additive toxicity (APExBIO).
• Zosuquidar shows higher selectivity for P-gp compared to first-generation inhibitors (e.g., verapamil or cyclosporine A), with negligible effect on CYP450-mediated drug metabolism (Next-Generation P-gp Inhibition).
• Benchmark studies confirm that zosuquidar can be used as a reference inhibitor in transporter assays (Caco-2, HEK293 transfectants) for P-gp substrate validation (Sun et al., 2025).

Applications, Limits & Misconceptions

Zosuquidar (LY335979) 3HCl is applied in basic, translational, and clinical research to dissect mechanisms of cancer multidrug resistance signaling, as well as to benchmark P-gp activity in transport assays. It is integral to drug screening pipelines for identifying P-gp substrates/inhibitors and for MDR reversal studies in both hematologic and solid tumor models.

Common Pitfalls or Misconceptions

• P-gp specificity: Zosuquidar is not intended for inhibition of non-P-gp ABC transporters such as MRP1 or BCRP.
• Pharmacokinetic neutrality: Zosuquidar does not significantly alter the systemic pharmacokinetics of co-administered chemotherapeutics at recommended concentrations (Sun et al., 2025).
• Concentration window: Effects are not observed below 0.05 μM or above 10 μM due to solubility and cytotoxicity constraints.
• Storage limitations: Working solutions are unstable beyond 24 hours at room temperature; long-term storage should be at –20°C in DMSO.
• Not a clinical MDR therapy: Zosuquidar is primarily a research tool and is not approved for general clinical use in MDR reversal outside of investigational trials.

This article extends the systems-level pharmacology covered in Zosuquidar (LY335979) 3HCl: Systems Pharmacology of P-gp by providing more granular, evidence-backed workflow guidance and benchmark data for MDR research. Compared to Zosuquidar: P-glycoprotein Modulator for Effective MDR Reversal, this article details chemical properties and storage parameters crucial for reproducibility in laboratory settings.

Workflow Integration & Parameters

• Preparation: Zosuquidar (LY335979) 3HCl is supplied as a powder by APExBIO (SKU: A3956). It is soluble in DMSO up to 10 mM; dilute freshly in buffer prior to use (product page).
• Storage: Store powder at –20°C. Avoid repeated freeze–thaw cycles. Working solutions in aqueous buffer are stable for <24h at 4°C.
• Assay recommendation: For in vitro P-gp inhibition, use 0.1–1 μM zosuquidar in cell-based efflux or cytotoxicity assays (e.g., Caco-2, HEK293-P-gp transfectants, or MDR cancer cell lines).
• In vivo protocols: Dose in murine MDR models at 5–25 mg/kg via intravenous or oral administration, with reference to published pharmacokinetic studies (Sun et al., 2025).
• Controls: Always include vehicle and non-P-gp inhibitor controls. For benchmarking, compare to first- and second-generation P-gp inhibitors.

Conclusion & Outlook

Zosuquidar (LY335979) 3HCl, as provided by APExBIO, is a best-in-class tool for precise and selective inhibition of P-glycoprotein, facilitating robust MDR reversal in cancer research. Its high specificity, reproducible activity, and defined chemical parameters make it suitable for mechanistic studies and drug screening workflows. Future research may expand its utility in combination regimens and in advanced models of transporter-mediated drug resistance.